Non-Integrating Lentiviral Vectors
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Lentiviral vectors are among the most efficient gene transfer tools for dividing and non-dividing cells. However, insertional mutagenesis has been observed in clinical trials with oncoretroviral vectors and this has prompted detailed study of genotoxicty of all integrating vectors. For many applications, avoiding integration is the most straightforward approach to overcome this problem and is facilitated by the extensive studies of the integrating mechanisms of lentiviruses. Indeed, non-integrating lentiviral vectors have been developed by mutating the integrase gene or by modifying the attachment sequences of the LTRs. In this review, we first consider on the toxicity associated with integration and on lentivirus integrase biology, and discuss the implications of integrase mutant studies for the development of non-integrating lentiviral vectors. We review published data concerning non-integrating lentiviral vectors with particular focus on their residual integration and transgene expression efficiency. Finally, the latest advances in the development of genetic engineering tools derived from non-integrating lentiviral vectors are presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832 · cited 1×
“This view evolved after the human and mouse genomes were sequenced, allowing integration sites to be accurately mapped; it was then found that lentiviruses and lentiviralderived vectors integrate preferentially into transcriptionally active genes [18-22], Murine Leukemia Virus (MLV) integrates mainly into promoter reg…”
BackgroundNaldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 3×
“As mentioned above, non-integrating vectors were initially considered to be non-functional because of a lack of transgene expression, unlike their integrative counterparts [62, 63]; this led to the view that episomal forms of lentiviral vectors could not be transcribed.”
BackgroundTranscription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305 · cited 1×
“This view evolved after the human and mouse genomes were sequenced, allowing integration sites to be accurately mapped; it was then found that lentiviruses and lentiviralderived vectors integrate preferentially into transcriptionally active genes [18-22], Murine Leukemia Virus (MLV) integrates mainly into promoter reg…”
BackgroundAAV vector integration sites in mouse hepatocellular carcinoma
Donsante, A., Miller, D. G., Li, Y., Vogler, C., Brunt, E. M., Russell, D. W., & Sands, M. S. (2007) · Science · doi:10.1126/science.1142658 · Cited by 662 · cited 1×
“Thus, NIL vectors are a genuine alternative to other vectors, like adeno-associated vectors (AAV); this is important because, although AAV were long considered to be safe non-integrating vectors, there is now evidence that they randomly integrate into somatic cells in vivo and into blood hematopoietic stem cells [98],…”
BackgroundDurai, S. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki912 · Cited by 522
Effective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460 · cited 7×
“NIL vectors with a clearly non-integrating phenotype can be obtained by introducing mutations into any of these regions [71-73, 84] (Table 1).”
BackgroundInfluentialMultiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication
Engelman, A., Englund, G., Orenstein, J. M., Martin, M. A., & Craigie, R. (1995) · Journal of Virology · doi:10.1128/jvi.69.5.2729-2736.1995 · Cited by 445 · cited 1×
“In contrast, several studies by other groups demonstrated the expression of the viral genes tat [49-52], nef [53] and p24 and RT [54] by using different types of integrase mutants.”
ResultRetroviral DNA integration: viral and cellular determinants of target-site selection
Lewinski, M. K., Yamashita, M., Emerman, M., Ciuffi, A., Marshall, H., Crawford, G., Collins, F., Shinn, P., Leipzig, J., Hannenhalli, S., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020060 · Cited by 364
Themis, M., Waddington, S. N., Schmidt, M., von Kalle, C., Wang, Y., Al-Allaf, F., Gregory, L. G., Nivsarkar, M., Themis, M., Holder, M. V., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.358 · Cited by 243 · cited 1×
“Generalizations in this matter should however be stated carefully since some lentiviral vectors can be transformant in embryonic tissues (equine infectious anemia virus (EIAV) but not HIV-derived vectors) [30] and favor clonality in vitro [31].”
BackgroundLeavitt, A. D., Robles, G., Alesandro, N., & Varmus, H. E. (1996) · Journal of Virology · doi:10.1128/jvi.70.2.721-728.1996 · Cited by 232
Lentiviral vectors for enhanced gene expression in human hematopoietic cells
Ramezani, A., Hawley, T. S., & Hawley, R. G. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0190 · Cited by 217 · cited 1×
“In parallel, the efficiency of lentiviral vector transduction was significantly improved mainly by stabilizing and increasing transgene expression [67-69] and by rescuing a deficient nuclear import phenotype present in first generation of vectors [70].”
BackgroundTransient Gene Expression by Nonintegrating Lentiviral Vectors
Nightingale, S. J., Hollis, R. P., Pepper, K. A., Petersen, D., Yu, X.-J., Yang, C., Bahner, I., & Kohn, D. B. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.008 · Cited by 192
Adeno-Associated Virus Integration: Virus versus Vector
Smith, R. H. (2008) · Gene Therapy · doi:10.1038/gt.2008.55 · Cited by 178 · cited 1×
“Thus, NIL vectors are a genuine alternative to other vectors, like adeno-associated vectors (AAV); this is important because, although AAV were long considered to be safe non-integrating vectors, there is now evidence that they randomly integrate into somatic cells in vivo and into blood hematopoietic stem cells [98],…”
BackgroundIn Vivo Analysis of Retroviral Integrase Structure and Function
Engelman, A. (1999) · Advances in Virus Research · doi:10.1016/s0065-3527(08)60309-7 · Cited by 176 · cited 2×
“In 1999 Alan Engelman proposed distinguishing between two classes of integrase mutations: i) class I mutations that specifically block the integration, and ii) class II mutations with pleiotropic repercussions on the viral cycle [60].”
BackgroundStable Gene Transfer to Muscle Using Non-integrating Lentiviral Vectors
Apolonia, L., Waddington, S. N., Fernandes, C., Ward, N. J., Bouma, G., Blundell, M. P., Thrasher, A. J., Collins, M. K., & Philpott, N. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300281 · Cited by 174 · cited 9×
“NIL vectors with a clearly non-integrating phenotype can be obtained by introducing mutations into any of these regions [71-73, 84] (Table 1).”
BackgroundInfluentialMasuda, T., Planelles, V, Krogstad, P., & Chen, I. S. (1995) · Journal of Virology · doi:10.1128/jvi.69.11.6687-6696.1995 · Cited by 154 · cited 4×
“Mutating the CA dinucleotide in the U3 and U5 of the LTRs ( att) inhibits viral integration [75].”
BackgroundMethodResultInfluentialTargeted Genome Modifications Using Integrase-deficient Lentiviral Vectors
Cornu, T. I., & Cathomen, T. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300345 · Cited by 105 · cited 6×
“NIL vectors with a clearly non-integrating phenotype can be obtained by introducing mutations into any of these regions [71-73, 84] (Table 1).”
BackgroundMethodResultInfluentialSuccessful Immunization with a Single Injection of Non-integrating Lentiviral Vector
Negri, D. R., Michelini, Z., Baroncelli, S., Spada, M., Vendetti, S., Buffa, V., Bona, R., Leone, P., Klotman, M. E., & Cara, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300241 · Cited by 84 · cited 3×
“Another application that seems plausible for NIL vectors is vaccination by transient expression of an antigen in peripheral tissues [74] or dendritic cells [97].”
Background
Cited by
Tracking genome engineering outcome at individual DNA breakpoints
Certo, M. T., Ryu, B. Y., Annis, J. E., Garibov, M., Jarjour, J., Rawlings, D. J., & Scharenberg, A. M. (2011) · Nature Methods · doi:10.1038/nmeth.1648 · Cited by 318
Human Studies of Angiogenic Gene Therapy
Gupta, R., Tongers, J., & Losordo, D. W. (2009) · Circulation Research · doi:10.1161/circresaha.109.200386 · Cited by 276
Viral vectors for gene delivery to the central nervous system
Lentz, T. B., Gray, S. J., & Samulski, R. J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.014 · Cited by 271
Strategies to Address Chimeric Antigen Receptor Tonic Signaling
Ajina, A., & Maher, J. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1097 · Cited by 237
Integration-deficient Lentiviral Vectors: A Slow Coming of Age
Wanisch, K., & Yáñez-Muñoz, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.122 · Cited by 222
Metadata
- Authors
- Sarkis, C., Philippe, S., Mallet, J., & Serguera, C.
- Venue
- Current Gene Therapy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-12-01
- Volume
- 8
- Issue
- 6
- Pages
- 430-437
- ISSN
- 1566-5232 (ISSN-L)
- OpenAlex
- W3105032491
- Cited by
- 74
- References
- 18
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.